Abuse deterrent and anti-dose dumping pharmaceutical salts useful for the treatment of attention deficit/hyperactivity disorder

1. A pharmaceutical composition comprising a drug substance consisting essentially of a pharmaceutically acceptable organic acid addition salt of an amine containing pharmaceutically active compound wherein said amine containing pharmaceutical active compound is polymorphic racemic-methylphenidate pamoate with an endothermic phase change transition of at least 75 J/gram at greater than 200° C.

2. A pharmaceutical composition comprising a drug substance consisting essentially of a pharmaceutically acceptable organic acid addition salt of an amine containing pharmaceutically active compound wherein said amine containing pharmaceutically active compound is selected from the group consisting of racemic or single isomer ritalinic acid or phenethylamine derivatives and said drug substance has a physical form selected from amorphous and polymorphic wherein said drug substance is selected from the group consisiting of polymorphic racemic-methylphenidate pamoate with a PXRD diffractogram of FIG. 6 and amorphous racemic-methylphenidate pamoate with a PXRD diffractogram of FIG. 3 .

3. A drug substance consisting essentially of a pharmaceutically acceptable organic acid addition salt of an amine containing pharmaceutically active compound wherein said amine containing pharmaceutically active compound is selected from the group consisting of:

amorphous racemic-methylphenidate pamoate with at least one property selected from the group consisting of:

an endothermic phase change of at least 70 J/gram at greater than 200° C.; and

a PXRD diffractogram of FIG. 3 ;

polymorphic racemic-methylphenidate pamoate with at least one property selected from the group consisting of:

an endothermic phase change transition of at least 75 J/gram at greater than 200° C.; and

a PXRD diffractogram of FIG. 6 ;

polymorphic racemic-methylphenidate xinafoate with at least one property selected from the group consisting of:

an endothermic phase change of at least 75 J/gram at greater than 155° C.; and

a PXRD diffractogram of FIG. 9 ;

amorphous d-methylphenidate pamoate with at least one property selected from the group consisting of:

an endothermic phase change of at least 45 J/gram at greater than 70° C.;

an endothermic phase change of at least 30 J/gram at greater than 180° C.; and

a PXRD diffractogram of FIG. 12 ;

polymorphic d-methylphenidate pamoate with at least one property selected from the group consisting of:

an endothermic phase change of at least 35 J/gram at greater than 185° C.; and

a PXRD diffractogram of FIG. 15 ;

amorphous d-methylphenidate xinafoate with at least one property selected from the group consisting of:

an endothermic phase change of at least 10 J/gram at greater than 45° C.;

an endothermic phase change of at least 50 J/gram at greater than 160° C.; and

a PXRD diffractogram of FIG. 18 ;

amorphous amphetamine pamoate with at least one property selected from the group consisting of:

an endothermic phase change of at least 10 J/gram at greater than 200° C.;

an endothermic phase change of at least 75 J/gram at greater than 220° C.; and

a PXRD diffractogram of FIG. 21 ;

polymorphic dextro-amphetamine pamoate with at least one property selected from the group consisting of:

an endothermic phase change of at least 60 J/gram at greater than 200° C.; and

a PXRD diffractogram of FIG. 24 ; and

polymorphic dextro-amphetamine xinafoate with at least one property selected from the group consisting of:

an endothermic phase change of at least 60 J/gram at greater than 125° C.; and

a PXRD diffractogram of FIG. 27 ;

wherein said drug substance is useful for the treatment of a therapeutic ailment administration and said drug substance exhibits abuse-deterrent properties when employed in non-therapeutic administration.

4. A drug product not susceptible to dose dumping wherein said drug product comprises a drug substance wherein said drug substance is a pharmaceutically acceptable organic acid salt of an amine containing pharmaceutically active compound selected from the group consisting of:

amorphous racemic-methylphenidate pamoate with at least one property selected from the group consisting of:

an endothermic phase change of at least 70 J/gram at greater than 200° C.; and

a PXRD diffractogram of FIG. 3 ;

polymorphic racemic-methylphenidate pamoate with at least one property selected from the group consisting of:

an endothermic phase change transition of at least 75 J/gram at greater than 200° C.; and

a PXRD diffractogram of FIG. 6 ;

polymorphic racemic-methylphenidate xinafoate with at least one property selected from the group consisting of:

an endothermic phase change of at least 75 J/gram at greater than 155° C.; and

a PXRD diffractogram of FIG. 9 ;

amorphous d-methylphenidate pamoate with at least one property selected from the group consisting of:

an endothermic phase change of at least 45 J/gram at greater than 70° C.;

an endothermic phase change of at least 30 J/gram at greater than 180° C.; and

a PXRD diffractogram of FIG. 12 ;

polymorphic d-methylphenidate pamoate with at least one property selected from the group consisting of:

an endothermic phase change of at least 35 J/gram at greater than 185° C.; and

a PXRD diffractogram of FIG. 15 ;

amorphous d-methylphenidate xinafoate with at least one property selected from the group consisting of:

an endothermic phase change of at least 10 J/gram at greater than 45° C.;

an endothermic phase change of at least 50 J/gram at greater than 160° C.; and

a PXRD diffractogram of FIG. 18 ;

amorphous amphetamine pamoate with at least one property selected from the group consisting of:

an endothermic phase change of at least 10 J/gram at greater than 200° C.;

an endothermic phase change of at least 75 J/gram at greater than 220° C.; and

a PXRD diffractogram of FIG. 21 ;

polymorphic dextro-amphetamine pamoate with at least one property selected from the group consisting of:

an endothermic phase change of at least 60 J/gram at greater than 200° C.; and

a PXRD diffractogram of FIG. 24 ; and

polymorphic dextro-amphetamine xinafoate with at least one property selected from the group consisting of:

an endothermic phase change of at least 60 J/gram at greater than 125° C.; and

a PXRD diffractogram of FIG. 27 ; and said drug substance meets at least one condition in 0.1 N HCl selected from the group consisting of:

no more than 35% of said drug substance is released at 30 minutes with 5 wt % ethanol in said 0.1 N HCl;

the percentage of said drug substance released with at least 5 wt % ethanol in said 0.1 N HCl is no more than a percentage of said drug substance released in said 0.1 N HCl without ethanol; and

the percentage of drug substance released with 40 wt % ethanol in 0.1 N HCl does not exceed 60% while the percentage of drug substance released under the conditions selected from water, 0.1 N HCl, 5 wt % ethanol in 0.1 N HCl and 20 wt % ethanol in 0.1 N HCl does not exceed the drug substance released with 40 wt % ethanol in 0.1 N HCl.

5. The drug product not susceptible to dose dumping of claim 4 wherein no more than 35% of said drug substance is released at 45 minutes with 5 wt % ethanol in said 0.1 N HCl.

6. A drug substance consisting essentially of a pharmaceutically acceptable organic acid addition salt of an amine containing pharmaceutically active compound wherein said amine containing pharmaceutically active compound is polymorphic racemic-methylphenidate pamoate with an endothermic phase change of at least 75 J/gram at greater than 200° C.

7. A pharmaceutical composition comprising a drug substance consisting essentially of a pharmaceutically acceptable organic acid addition salt of an amine containing pharmaceutically active compound selected from the group consisting of:

amorphous racemic-methylphenidate pamoate with at least one property selected from the group consisting of:

an endothermic phase change of at least 70 J/gram at greater than 200° C.;

a PXRD diffractogram of FIG. 3 ;

polymorphic racemic-methylphenidate pamoate with at least one property selected from the group consisting of:

an endothermic phase change transition of at least 75 J/gram at greater than 200° C.;

a PXRD diffractogram of FIG. 6 ;

polymorphic racemic-methylphenidate xinafoate with at least one property selected from the group consisting of:

an endothermic phase change of at least 75 J/gram at greater than 155° C.;

a PXRD diffractogram of FIG. 9 ;

amorphous d-methylphenidate pamoate with at least one property selected from the group consisting of:

an endothermic phase change of at least 45 J/gram at greater than 70° C.;

an endothermic phase change of at least 30 J/gram at greater than 180° C.;

a PXRD diffractogram of FIG. 12 ;

polymorphic d-methylphenidate pamoate with at least one property selected from the group consisting of:

an endothermic phase change of at least 35 J/gram at greater than 185° C.;

a PXRD diffractogram of FIG. 15 ;

amorphous d-methylphenidate xinafoate with at least one property selected from the group consisting of:

an endothermic phase change of at least 10 J/gram at greater than 45° C.;

an endothermic phase change of at least 50 J/gram at greater than 160° C.;

a PXRD diffractogram of FIG. 18 ;

amorphous amphetamine pamoate with at least one property selected from the group consisting of:

an endothermic phase change of at least 10 J/gram at greater than 200° C.;

an endothermic phase change of at least 75 J/gram at greater than 220° C.;

a PXRD diffractogram of FIG. 21 ;

polymorphic dextro-amphetamine pamoate with at least one property selected from the group consisting of:

an endothermic phase change of at least 60 J/gram at greater than 200° C.;

a PXRD diffractogram of FIG. 24 ; and

polymorphic dextro-amphetamine xinafoate with at least one property selected from the group consisting of:

an endothermic phase change of at least 60 J/gram at greater than 125° C.;

a PXRD diffractogram of FIG. 27 .

8. A pharmaceutical composition comprising a drug substance selected from the group consisting of:

polymorphic racemic-methylphenidate pamoate with at least one property selected from the group consisting of:

an endothermic phase change transition of at least 75 J/gram at greater than 200° C.; and

a PXRD diffractogram of FIG. 6 ;

polymorphic racemic-methylphenidate xinafoate with at least one property selected from the group consisting of:

an endothermic phase change of at least 75 J/gram at greater than 155° C.; and

a PXRD diffractogram of FIG. 9 ;

polymorphic d-methylphenidate pamoate with at least one property selected from the group consisting of:

an endothermic phase change of at least 35 J/gram at greater than 185° C.; and

a PXRD diffractogram of FIG. 15 ;

polymorphic dextro-amphetamine pamoate with at least one property selected from the group consisting of:

an endothermic phase change of at least 60 J/gram at greater than 200° C.; and

a PXRD diffractogram of FIG. 24 ; and

polymorphic dextro-amphetamine xinafoate with at least one property selected from the group consisting of:

an endothermic phase change of at least 60 J/gram at greater than 125° C.; and

a PXRD diffractogram of FIG. 27 .

9. A pharmaceutical composition comprising a drug substance consisting essentially of a pharmaceutically acceptable organic acid addition salt of an amine containing pharmaceutically active compound selected from the group consisting of:

amorphous racemic-methylphenidate pamoate with at least one property selected from the group consisting of:

an endothermic phase change of at least 70 J/gram at greater than 200° C.; and

a PXRD diffractogram of FIG. 3 ;

polymorphic racemic-methylphenidate pamoate with at least one property selected from the group consisting of:

an endothermic phase change transition of at least 75 J/gram at greater than 200° C.; and

a PXRD diffractogram of FIG. 6 ;

amorphous d-methylphenidate pamoate with at least one property selected from the group consisting of:

an endothermic phase change of at least 45 J/gram at greater than 70° C.;

an endothermic phase change of at least 30 J/gram at greater than 180° C.; and

a PXRD diffractogram of FIG. 12 ;

amorphous d-methylphenidate xinafoate with at least one property selected from the group consisting of:

an endothermic phase change of at least 10 J/gram at greater than 45° C.;

an endothermic phase change of at least 50 J/gram at greater than 160° C.; and

a PXRD diffractogram of FIG. 18 ;

amorphous amphetamine pamoate with at least one property selected from the group consisting of:

an endothermic phase change of at least 10 J/gram at greater than 200° C.;

an endothermic phase change of at least 75 J/gram at greater than 220° C.; and

a PXRD diffractogram of FIG. 21 .